Blood tests measuring phosphorylated tau and amyloid-related biomarkers can identify Alzheimer’s-associated brain pathology with high accuracy, but they are not interchangeable with population screening or a complete dementia diagnosis.
C2N Diagnostics’ FDA-cleared PrecivityAD2 combines amyloid and tau measurements in a mass-spectrometry test intended to aid assessment of symptomatic adults aged 40 and older.
Alzheimer’s blood tests are moving from specialist research into clinical practice after real-world evidence showed that biomarker results sharply improved diagnostic accuracy. The opportunity is substantial, but differences between assays, inappropriate screening and laboratory-quality failures could undermine confidence.